The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

Chronic kidney disease has been linked to yo-yo dieting (also known as body-weight cycling) in the general population, which ...

Body-weight cycling (also known as yo-yo dieting) has been shown to significantly increase the risk of kidney disease in ...

Statins, which are prescription drugs that can reduce cholesterol levels and lower the risk for heart disease, don’t affect kidney function, new research shows.

Patients with CKD who use antiresorptive drugs for tumor-related disorders or oral corticosteroids may be at increased risk for osteonecrosis of the jaw.

In line with trial results, real-world data suggest GLP-1 receptor agonists have certain benefits in patients with moderate to severe chronic kidney disease (CKD).

Repeated weight loss and gain — known as yo-yo dieting — has been linked to kidney disease in type 1 diabetes patients. A ...

Adults with type 1 diabetes who partake in weight cycling and repeatedly lose and regain body weight are more likely to develop diabetic kidney disease, researchers reported in The Journal of Clinical ...

The present case and others in the literature indicate that the presence of hydronephrosis, even if associated with no apparent glomerular ... kidney. In patients with cystic renal diseases ...

WASHINGTON—Body-weight cycling (also known as yo-yo dieting) has been shown to significantly increase the risk of kidney disease in people with type 1 ...

The latest semaglutide (Ozempic; Novo Nordisk) approval is set to tackle a major need for patients with both type 2 diabetes ...